Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder

Myoung Jin Choi, Rhee Hun Kang, Se Won Lim, Kang Seob Oh, Min-Soo Lee

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

The brain-derived neurotrophic factor (BDNF) gene is a candidate gene for influencing the clinical response to treatment with antidepressants. The purpose of this study was to determine the relationship between the Val66Met polymorphism in the BNDF gene and the response to citalopram in a Korean population with major depressive disorder (MDD). Citalopram was administered for 8 weeks to the 83 patients who completed this study. We found that the genotype, allele, and allele-carrier distributions for the Val66Met polymorphism differed significantly between responders (Rp) and nonresponders (Non-Rp). The frequency of M-allele carriers (VM + MM) was higher in Rp than in Non-Rp (χ2 = 8.926, p = 0.003, OR = 4.375, 95%CI = 1.609-11.892), as was the M-allele frequency (χ2 = 6.879, p = 0.009, OR = 2.500, 95%CI = 1.249-5.005). There were also significant differences in the core (p = 0.012) and activity (p = 0.008) scores. Patients carrying the M-allele had a lower score. Also, patients carrying the M-allele tended to have lower psychic anxiety (p = 0.072). The percentage change in the total HAM-D score was higher for M-allele carriers (VM + MM allele) than for noncarriers (p = 0.034) after 8 weeks of medication. We found that the genotype, allele, and allele-carrier distributions did not differ significantly between MDD patients and normal controls. These results suggest that the Val66Met polymorphism of BDNF is associated with citalopram efficacy, with M-allele carriers responding better to citalopram treatment. Moreover, the Val66Met polymorphism was correlated with improvements in core, activity, and psychic anxiety symptoms.

Original languageEnglish
Pages (from-to)176-182
Number of pages7
JournalBrain Research
Volume1118
Issue number1
DOIs
Publication statusPublished - 2006 Nov 6

Fingerprint

Citalopram
Brain-Derived Neurotrophic Factor
Major Depressive Disorder
Alleles
Genes
Gene Frequency
Anxiety
Genotype
Antidepressive Agents

Keywords

  • Antidepressant
  • Brain-derived neurotrophic factor
  • Citalopram
  • Major depressive disorder
  • Polymorphism
  • Treatment response

ASJC Scopus subject areas

  • Neuroscience(all)
  • Molecular Biology
  • Developmental Biology
  • Clinical Neurology

Cite this

Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. / Choi, Myoung Jin; Kang, Rhee Hun; Lim, Se Won; Oh, Kang Seob; Lee, Min-Soo.

In: Brain Research, Vol. 1118, No. 1, 06.11.2006, p. 176-182.

Research output: Contribution to journalArticle

Choi, Myoung Jin ; Kang, Rhee Hun ; Lim, Se Won ; Oh, Kang Seob ; Lee, Min-Soo. / Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. In: Brain Research. 2006 ; Vol. 1118, No. 1. pp. 176-182.
@article{88100ca6441340b3aab5e33334bb056f,
title = "Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder",
abstract = "The brain-derived neurotrophic factor (BDNF) gene is a candidate gene for influencing the clinical response to treatment with antidepressants. The purpose of this study was to determine the relationship between the Val66Met polymorphism in the BNDF gene and the response to citalopram in a Korean population with major depressive disorder (MDD). Citalopram was administered for 8 weeks to the 83 patients who completed this study. We found that the genotype, allele, and allele-carrier distributions for the Val66Met polymorphism differed significantly between responders (Rp) and nonresponders (Non-Rp). The frequency of M-allele carriers (VM + MM) was higher in Rp than in Non-Rp (χ2 = 8.926, p = 0.003, OR = 4.375, 95{\%}CI = 1.609-11.892), as was the M-allele frequency (χ2 = 6.879, p = 0.009, OR = 2.500, 95{\%}CI = 1.249-5.005). There were also significant differences in the core (p = 0.012) and activity (p = 0.008) scores. Patients carrying the M-allele had a lower score. Also, patients carrying the M-allele tended to have lower psychic anxiety (p = 0.072). The percentage change in the total HAM-D score was higher for M-allele carriers (VM + MM allele) than for noncarriers (p = 0.034) after 8 weeks of medication. We found that the genotype, allele, and allele-carrier distributions did not differ significantly between MDD patients and normal controls. These results suggest that the Val66Met polymorphism of BDNF is associated with citalopram efficacy, with M-allele carriers responding better to citalopram treatment. Moreover, the Val66Met polymorphism was correlated with improvements in core, activity, and psychic anxiety symptoms.",
keywords = "Antidepressant, Brain-derived neurotrophic factor, Citalopram, Major depressive disorder, Polymorphism, Treatment response",
author = "Choi, {Myoung Jin} and Kang, {Rhee Hun} and Lim, {Se Won} and Oh, {Kang Seob} and Min-Soo Lee",
year = "2006",
month = "11",
day = "6",
doi = "10.1016/j.brainres.2006.08.012",
language = "English",
volume = "1118",
pages = "176--182",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder

AU - Choi, Myoung Jin

AU - Kang, Rhee Hun

AU - Lim, Se Won

AU - Oh, Kang Seob

AU - Lee, Min-Soo

PY - 2006/11/6

Y1 - 2006/11/6

N2 - The brain-derived neurotrophic factor (BDNF) gene is a candidate gene for influencing the clinical response to treatment with antidepressants. The purpose of this study was to determine the relationship between the Val66Met polymorphism in the BNDF gene and the response to citalopram in a Korean population with major depressive disorder (MDD). Citalopram was administered for 8 weeks to the 83 patients who completed this study. We found that the genotype, allele, and allele-carrier distributions for the Val66Met polymorphism differed significantly between responders (Rp) and nonresponders (Non-Rp). The frequency of M-allele carriers (VM + MM) was higher in Rp than in Non-Rp (χ2 = 8.926, p = 0.003, OR = 4.375, 95%CI = 1.609-11.892), as was the M-allele frequency (χ2 = 6.879, p = 0.009, OR = 2.500, 95%CI = 1.249-5.005). There were also significant differences in the core (p = 0.012) and activity (p = 0.008) scores. Patients carrying the M-allele had a lower score. Also, patients carrying the M-allele tended to have lower psychic anxiety (p = 0.072). The percentage change in the total HAM-D score was higher for M-allele carriers (VM + MM allele) than for noncarriers (p = 0.034) after 8 weeks of medication. We found that the genotype, allele, and allele-carrier distributions did not differ significantly between MDD patients and normal controls. These results suggest that the Val66Met polymorphism of BDNF is associated with citalopram efficacy, with M-allele carriers responding better to citalopram treatment. Moreover, the Val66Met polymorphism was correlated with improvements in core, activity, and psychic anxiety symptoms.

AB - The brain-derived neurotrophic factor (BDNF) gene is a candidate gene for influencing the clinical response to treatment with antidepressants. The purpose of this study was to determine the relationship between the Val66Met polymorphism in the BNDF gene and the response to citalopram in a Korean population with major depressive disorder (MDD). Citalopram was administered for 8 weeks to the 83 patients who completed this study. We found that the genotype, allele, and allele-carrier distributions for the Val66Met polymorphism differed significantly between responders (Rp) and nonresponders (Non-Rp). The frequency of M-allele carriers (VM + MM) was higher in Rp than in Non-Rp (χ2 = 8.926, p = 0.003, OR = 4.375, 95%CI = 1.609-11.892), as was the M-allele frequency (χ2 = 6.879, p = 0.009, OR = 2.500, 95%CI = 1.249-5.005). There were also significant differences in the core (p = 0.012) and activity (p = 0.008) scores. Patients carrying the M-allele had a lower score. Also, patients carrying the M-allele tended to have lower psychic anxiety (p = 0.072). The percentage change in the total HAM-D score was higher for M-allele carriers (VM + MM allele) than for noncarriers (p = 0.034) after 8 weeks of medication. We found that the genotype, allele, and allele-carrier distributions did not differ significantly between MDD patients and normal controls. These results suggest that the Val66Met polymorphism of BDNF is associated with citalopram efficacy, with M-allele carriers responding better to citalopram treatment. Moreover, the Val66Met polymorphism was correlated with improvements in core, activity, and psychic anxiety symptoms.

KW - Antidepressant

KW - Brain-derived neurotrophic factor

KW - Citalopram

KW - Major depressive disorder

KW - Polymorphism

KW - Treatment response

UR - http://www.scopus.com/inward/record.url?scp=33750371336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750371336&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2006.08.012

DO - 10.1016/j.brainres.2006.08.012

M3 - Article

C2 - 16979146

AN - SCOPUS:33750371336

VL - 1118

SP - 176

EP - 182

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1

ER -